Seniors should have the flu jab this winter, say experts
Peregrine Pharmaceuticals, Inc. has announced that updated preliminary data from the first stage of its Phase II trial evaluating bavituximab in combination with docetaxel showed that 10 of 14 (71%) evaluable breast cancer patients achieved an objective tumor response according to RECIST criteria. The company also reported that patient screening has begun in the
Full Post: Peregrine Pharmaceuticals reports on phase II trial of Bavituximab plus Docetaxel in advanced breast cancer
Despite recent doubts about its effectiveness, the influenza vaccine does give valuable protection against illness, hospital admission and death caused by influenza, and people over 65 should have the flu jab this winter, say experts on bmj.com.
Several prominent media articles have suggested that the flu vaccination programme for the over 65s is not worthwhile. Rachel Jordan from the University of Birmingham and Jeremy Hawker from the Health Protection Agency review the evidence surrounding the ongoing controversy.
The annual influenza vaccination campaign is one of the most successful public health programmes in the UK, with 78% of people over 70 receiving the jab, the highest in Europe.
However, according to the authors, it is notoriously difficult to find out the full effectiveness of the influenza vaccine. For instance, the vaccine may not fully match the strain of a particular year, influenza seasons vary in timing and strength, and few studies measure influenza specific outcomes.
Previous trials have shown that the vaccine is effective in preventing influenza in those over 60. But recently, some researchers have questioned the validity and plausibility of findings for other less specific benefits provided by the vaccine, such as a reported reduction in hospital admissions for influenza and pneumonia by 27% and particularly all cause deaths by 48%. This would imply that most deaths in winter were due to influenza.
Large, routinely-collected datasets analysed in some of these studies had limited patients’ details which did not include functional status, disease severity, or smoking status. Other studies which tried to allow for this, have shown benefits to be smaller but significant, whereas one reported no clear effect on all cause deaths. Influenza activity was, however, relatively low in several of these years.
Despite these methodological problems and disagreements, most experts agree that although more evidence is needed on the precise effectiveness of the vaccine, it has some benefit and the vaccination programmes should continue, say the authors.
“Influenza causes substantial mortality and morbidity in older people, and even if the more general all cause mortality benefit may be lower than previously thought, the current vaccine programme offers older people valuable protection against illness, hospital admissions, and mortality specific to influenza, should they be exposed this winter”, say the authors.
They conclude by calling for resources to develop more effective vaccines, better forms of delivery of the vaccine for the elderly, and ensuring that more healthcare workers who come into contact with elderly people are vaccinated.
The National Association of County and City Health Officials (NACCHO) has announced a donation of up to one million doses of FluMist (Influenza Virus Vaccine Live, Intranasal) by MedImmune in a partnership aimed at increasing influenza awareness and vaccinations in underserved communities and populations. NACCHO will make these donated doses of vaccine available to selected state
Full Post: NACCHO to donate up to one million doses of FluMist
The American College of Physicians (ACP) and the Infectious Diseases Society of America (IDSA) have released a joint statement on the importance of adult vaccination against an increasing number of vaccine-preventable diseases. The statement has been endorsed by 17 other medical societies representing a range of practice areas. According to the Centers for Disease Control
Full Post: Adults need vaccines to protect from preventable diseases, say medical societies
Although there is an effort to implement rapid response teams in hospitals throughout the country, new research suggests that they do not result in a reduced rate of cardiopulmonary arrests or deaths, according to a study in the December 3 issue of JAMA, the Journal of the American Medical Association. Previous studies have found that
Full Post: Use of rapid response team in hospital not linked with reduction in cardio arrests or deaths
Workers age 50-64 who received influenza vaccine lost substantially fewer days of work and worked fewer days while ill, according to a new study in the Feb. 1 issue of Clinical Infectious Diseases, now available online. Given the concerns about antiviral drug resistance among this year’s flu strains, the study highlights the importance of vaccination
Full Post: Influenza vaccine helps 50-64 year olds stay at work
Individuals younger than 50 who have been previously vaccinated do not appear to have a substantially different immune response to a half-dose of influenza vaccine than to a full dose, according to a report in the December 8/22 issue of Archives of Internal Medicine. This suggests that half-dose vaccination in healthy young individuals may be
Full Post: Half-dose vaccination in healthy young individuals may be effective in times of vaccine shortage